Evidence map›Paper›PMID 33195006›Full record

ArticleFrontiers in chemistry2020

High-Throughput Qualitative and Quantitative Drug Checking by MALDI HRMS.

Timothée Joye, Christèle Widmer, Roxane Morger Mégevand, Serge Longère, Marc Augsburger, Aurélien Thomas

Open access · goldAbstract read
In one paragraph

Article in Frontiers in chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Interpol Review of Drug Analysis 2019-2022.Forensic science international. Synergy · 2023
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Timothée JoyeForensic Toxicology and Chemistry Unit, CURML, Lausanne University Hospital, Geneva University Hospitals, Geneva, Switzerland.
Christèle WidmerForensic Toxicology and Chemistry Unit, CURML, Lausanne University Hospital, Geneva University Hospitals, Geneva, Switzerland.
Roxane Morger MégevandNuit Blanche?, Association Première Ligne, Geneva, Switzerland.
Serge LongèreNuit Blanche?, Association Première Ligne, Geneva, Switzerland.
Marc AugsburgerForensic Toxicology and Chemistry Unit, CURML, Lausanne University Hospital, Geneva University Hospitals, Geneva, Switzerland.
Aurélien ThomasForensic Toxicology and Chemistry Unit, CURML, Lausanne University Hospital, Geneva University Hospitals, Geneva, Switzerland.
University Centre of Legal Medicine · CHUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Illicit drugs are a global health problem, since both their acute and chronic consumption have negative impacts on the drug user's health. Drug checking facilities are receiving growing interest as they allow drug users to chemically analyze their product prior to consumption to assess the presence of adulterants or other non-expected substances. Such harm reduction programs allow the reduction of the risks associated with drug consumption without encouraging it. In particular, the emergence of new psychoactive substances (NPS) emphasizes the risk for the population increasing the diversity and the lability of illicit drugs on the market. Analytical developments are required to catch up with this rapid evolution and reduce the potential harm caused by such consumption. In this study, we developed a matrix-assisted laser desorption/ionization (MALDI) high-resolution mass spectrometry (HRMS) strategy for the high-throughput qualitative and quantitative analysis of drug checking samples. The use of online-based m/z cloud library for untargeted compound search improved the ability to identify unknown compounds. Sixty-seven drug checking samples were analyzed using this analytical strategy, allowing the detection of 10 designer drugs and several classical drugs of abuse (mainly cocaine and MDMA) as well as adulterants and contaminants. The results were then compared with routine analyses of the same samples using conventional approaches showing similar performance while removing the use of chromatographic separation thus resulting in a significant reduction of the time required for sample preparation and analysis. This study enlightens the potential of MALDI-HRMS as a high-throughput approach allowing to speed-up up to six times the identification and quantification of substances enabling to catch the fast changes on the drug of abuse market. This strategy could be an interesting alternative analytical approach, allowing better prevention and harm reduction for drug users.

Indexed as

drug checkinghigh throughputHRMSMALDIqualitativequantitative

Identifiers

PMID33195006
PMCPMC7477897
OpenAlexW3081478477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.